Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q2 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.83 million.

For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.